trending Market Intelligence /marketintelligence/en/news-insights/trending/3LG6LVYN7DZ2pXgbTvX3mg2 content esgSubNav
In This List

Report: WuXi Biologics prices HK$3.98B IPO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Report: WuXi Biologics prices HK$3.98B IPO

China-based WuXi Biologics (Cayman) Inc. priced its IPO at the top end of its guidance, Reuters reported, citing a source.

The company priced the issue of 193 million shares at HK$20.60 apiece to raise about HK$3.98 billion.

WuXi provides a comprehensive, integrated and customized range of services for the discovery, development and manufacturing of biologics.